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* Trend test. #time to tPA and B MI location used as covariates. Median time to ST res- 
olution increased significantly as dose irweased. a result opposite to that expected. 
Conclusion: In this randomized, dose-ranging trial, rPSGL-Ig, given in combination with 
tPA to a maximum dose of 75 mg. did not significantly improve ST resolution, infarct size, 
election fraction or clinical outcomes. 
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Background: It is well documented that angiogenesis plays a key role in the process of 
ventricular remodeling following acute myocardial infarction (AMI). However, the exact 
contribution of each of the numerous angiogenic agents in this process is still ah issue of 
debate. We sought to evaluate the role of free Insulin-like Growth Factor-l (fIGF-1) basic 
Fibroblast Growth Factor (bFGF) and Angiogenin (ANG), in AMI patients. 
Methods: 40 pts with first attack of AMI admitted and thrombolysed during the acute 
phase, were examined for plasma levels of ffGF-1, bFGF and ANG. measured by ELISA. 
and compared to those of 20 normal controls (NC) with mean values: 7.78 +0,75 ng/ml 
for flGF-1, I,62 + 053 pg/ml for bFGF and 210,12 + 256 ng/ml for ANG. Plasma sarn- 
ples were collected oh hospital admission (0 hours) and 3h, 6h. 9h, 12h, 16h, 24h, 36h, 
46h, 3 days, 4d, 5d, 7d, 15d and 30d thereafter. 
Results: Data is expressed as mean values -+ SEM. For the statistical analysis the non- 
parametric Wilcoxon test was used with p<O,O5 compared to NC (‘) and the relevant 
plasma value oh admission (^). fIGF-1 exhibited significantly high inrtial plasma levels at 
Oh (10,92+0,93’) followed by a gradual increase up to a maximum at 36h (1664 _+2,12’ 
A) succeeded by a progressive decline up to a minimum level at 30d (12,14 -+ 1,35’). 
bFGF developed a significant early peak at Oh (5,272 1,13’) followed by a steep decline 
leading to a nadir at 24h (1,63 -+ 0,46A), that was reversed leading to a late peak at 15d 
(6.93 + 2,06’). ANG also exhibited a double- peak increase at Oh (327,12 -+ 31,75*) as 
well as at 4d (305.86+29,44’) with the lowest plasma value at 24h (233.742 16.32”). 
Conclusions: Thus, the activation of the numerous angiogenic agents seems to be trig- 
gered at different time points. Some of them exhibit ah immediate peak shortly after AMI 
onset, probably as a result of acute hypoxia, while others develop an intermediate or a 
late peak, therefore exerting their cardioprotective potential in three distinct lines of 
defense. At the same time, they all act in concert to stimulate angiogenesis either by 
playing a pivotal role in its induction, or by manipulating its multiple steps later in an 
attempt to modulate ventricular remodeling and preserve cardiac function. 
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Background: PIA allele of glycoprotein llla gene has been shown to be associated with 
a higher risk for myocardral infarction and complications after coronary intervention. It is 
not clear, whether PIA allele carriage influences the degree of myocardial salvage in 
patients with acute myocardial infarction (AMI) treated with thrombolysis or stenting. 
Methods: We analyzed 292 patients enrolled in STOPAMll and STOPAMIP randomized 
trials that compared stenting plus abciximab with thrombolysis (alteplase alone or 
alteplase plus abciximab) in AMI. PIA genotype was performed with a TaqMan assay. 
Technetium99m sestamibi was injected before and 1-2 weeks after repedusion treat- 
ment to calculate the initial perfusion defect, final infarct size, and the proportion of initial 
defect salvaged with reperfusion (salvage index). Mortality was assessed in a period of 
16 months. 
Resulta The genotype distribution was as follows: PIA2/A2 in 3.4% PIAl/AP in 24.7% 
and PIAl/Al in 71.9% of patients. There were ho significant differences between PIA 
allele carriers and PIAl/AI patients in salvage index (0.45 vs 0.41, PcO.25) final infarct 
size (16.6% vs. 16.4% of left ventricle, PsO.46) as well as 16month mortality (6.5% 
vs.7.1%, P=O.69). The relation between PIA allele presence and salvage index was 
absent both in stenting and thrombolysis group. 
Conclusiomx PIA allele has no influence on the degree of myocardial salvage 
achieved with stenting or thrombolysis in patients with AMI. 
